吡咯替尼在ERBB2突变的非小细胞肺癌治疗中的研究进展

Progress in the treatment of pyrotinib in ERBB2 mutated non-small cell lung cancer

目前非小细胞肺癌的靶向治疗取得了阶段性的胜利,但一些靶点的治疗仍很棘手,在治疗效果及耐药机制方面也遇到了很大的挑战。本文就吡咯替尼在ERBB2基因突变的非小细胞肺癌治疗相关机制进行综述,以期为临床选择更好的肺癌治疗方案提供参考。

The targeted therapy of non-small cell lung cancer has achieved a phased victory currently,but it is still very difficult for some rare targets,and there are also great challenges in the treatment effect and drug resistance mechanism.With the continuous development of medical technology,in order to allow more lung cancer patients can have a better treatment plan.We report the therapeutic mechanism of Pyrolitinib in ERBB2 gene mutation in non-small cell lung cancer.